Loading...
Market
What will be the impact of MDMA-assisted therapy on PTSD patients in FDA trials by the end of 2024?
1
Resolution / Starting Odds
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened condition • 25%
Published results from FDA trials and peer-reviewed journals
Story
Bipartisan Lawmakers Urge FDA to Approve MDMA for PTSD Despite Concerns
Aug 5, 2024, 04:56 PM
Studies evaluating an ecstasy-based drug, MDMA, for FDA approval have been criticized for missing serious side effects, including worsened post-traumatic stress, suicidal thoughts, and bias among subjects. Despite these concerns, a bipartisan coalition of 80 senators and representatives has urged the FDA to consider approving MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Some subjects of the FDA's trial reported that the treatment was the only thing that helped them feel normal, although it was illegal post-study. Advocates argue that MDMA-AT has a proven efficacy for treating PTSD and could save Veterans' lives.
View original story
Similar markets
Approved without restrictions • 25%
Approved with restrictions • 25%
Not approved • 25%
Decision delayed • 25%
Effective for both PTSD and alcohol use disorder • 25%
Effective only for PTSD • 25%
Effective only for alcohol use disorder • 25%
Not effective for either condition • 25%
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Approval without restrictions • 25%
Approval with restrictions • 25%
Request for more data • 25%
Rejection • 25%
Efficacy • 25%
Safety concerns • 25%
Political pressure • 25%
Other • 25%
Significant positive results • 25%
Moderate positive results • 25%
No significant results • 25%
Negative results • 25%
0-10 states • 25%
11-20 states • 25%
21-30 states • 25%
31+ states • 25%
